Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TPST
Upturn stock ratingUpturn stock rating

Tempest Therapeutics Inc (TPST)

Upturn stock ratingUpturn stock rating
$9.48
Last Close (24-hour delay)
Profit since last BUY7.6%
upturn advisory
Consider higher Upturn Star rating
BUY since 3 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: TPST (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $9

1 Year Target Price $9

Analysts Price Target For last 52 week
$9 Target price
52w Low $5.35
Current$9.48
52w High $20.67

Analysis of Past Performance

Type Stock
Historic Profit -79.14%
Avg. Invested days 19
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 42.09M USD
Price to earnings Ratio -
1Y Target Price 9
Price to earnings Ratio -
1Y Target Price 9
Volume (30-day avg) 2
Beta -2.31
52 Weeks Range 5.35 - 20.67
Updated Date 08/15/2025
52 Weeks Range 5.35 - 20.67
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -14.52

Earnings Date

Report Date 2025-08-11
When -
Estimate -0.28
Actual -2.07

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -81.34%
Return on Equity (TTM) -322.57%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 36475726
Price to Sales(TTM) -
Enterprise Value 36475726
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.31
Shares Outstanding 4440160
Shares Floating 4139962
Shares Outstanding 4440160
Shares Floating 4139962
Percent Insiders 0.11
Percent Institutions 13.08

ai summary icon Upturn AI SWOT

Tempest Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Tempest Therapeutics Inc. is a clinical-stage oncology company focused on developing therapies that combine both tumor-directed and immune-mediated mechanisms. Founded in 2016, it has focused on advancing its pipeline through clinical trials.

business area logo Core Business Areas

  • Drug Development: Focused on discovering, developing, and commercializing small molecule therapeutics that modulate selective targets in the tumor microenvironment. Currently, the focus is on its lead drug candidate, TPST-1120.

leadership logo Leadership and Structure

Dr. Sam Whiting serves as President and CEO. The company has a board of directors overseeing its strategic direction and operations. The structure includes research and development, clinical operations, and business development functions.

Top Products and Market Share

overview logo Key Offerings

  • TPST-1120: An oral, selective PPARu03b1 antagonist being developed for liver cancer and other solid tumors. TPST-1120 is currently in clinical trials (Phase 1b/2). As a clinical-stage asset, it doesn't yet have market share or revenue. Competitors include other companies developing therapies for advanced solid tumors.

Market Dynamics

industry overview logo Industry Overview

The oncology therapeutics market is large and growing, driven by increasing cancer incidence and advances in targeted therapies and immunotherapies. The market is highly competitive, with many companies developing novel cancer treatments.

Positioning

Tempest Therapeutics aims to address unmet needs in cancer treatment by developing therapies that modulate the tumor microenvironment. Its competitive advantage lies in its targeted approach to PPARu03b1 antagonism and its potential to combine with other therapies.

Total Addressable Market (TAM)

The global oncology market is estimated to be several hundred billion USD. Tempest's initial target indication of liver cancer represents a multi-billion dollar market opportunity. Their positioning relies on clinical success to capture part of this TAM.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic approach targeting PPARu03b1
  • Clinical-stage pipeline
  • Experienced management team

Weaknesses

  • Reliance on a single lead asset (TPST-1120)
  • No current revenue stream
  • High cash burn rate associated with drug development

Opportunities

  • Positive clinical trial results for TPST-1120
  • Partnerships with larger pharmaceutical companies
  • Expansion into other cancer indications

Threats

  • Clinical trial failures
  • Competition from established oncology therapies
  • Regulatory hurdles
  • Funding risks due to market volatility

Competitors and Market Share

competitor logo Key Competitors

  • GILD
  • BMY
  • MRK

Competitive Landscape

Tempest faces significant competition from established pharmaceutical companies with larger resources and broader oncology portfolios. Their success depends on differentiating TPST-1120 and demonstrating its efficacy in clinical trials.

Growth Trajectory and Initiatives

Historical Growth: As a clinical-stage company, Tempest's historical growth has been marked by the progress of its clinical trials and milestones in drug development.

Future Projections: Future growth is contingent on the successful development and commercialization of TPST-1120 and any other pipeline candidates. Analyst projections are based on the potential market for these therapies.

Recent Initiatives: Recent initiatives include advancing TPST-1120 through clinical trials and exploring potential partnerships for further development and commercialization.

Summary

Tempest Therapeutics is a high-risk, high-reward clinical-stage company. Its success depends on the positive clinical trial outcomes of its lead drug candidate, TPST-1120. While it faces competition from larger pharmaceutical companies and regulatory hurdles, successful development could lead to significant growth and market opportunities. Monitoring cash flow, clinical milestones, and market sentiment is crucial for investors.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Tempest Therapeutics Inc. Investor Relations
  • SEC Filings
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is estimated and may vary. All financial data is based on the most recent available information, which may be subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Tempest Therapeutics Inc

Exchange NASDAQ
Headquaters Brisbane, CA, United States
IPO Launch date 2012-11-12
CEO, President & Director Mr. Stephen R. Brady J.D., LLM
Sector Healthcare
Industry Biotechnology
Full time employees 24
Full time employees 24

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.